Streetbeat News

Earnings

EGRX

Eagle Pharmaceuticals has delayed its Q3 results to review potential adjustments related to the reporting of sales of PEMFEXY. The company also expects to revise its FY23 guidance.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:22 pm

IKNA

Ikena Oncology Inc (NASDAQ:IKNA) shared initial data from its ongoing Phase 1 trial of IK-930, a potent Hippo-pathway inhibitor used in cancer treatment. The company reported stable disease in all seven patients with epithelioid hemangioendothelioma (EHE) treated with IK-930. Three of these patients experienced tumor shrinkage. A combination cohort for IK-930 and osimertinib in patients with EGFR-mutant non-small cell lung cancer is planned for 2024. Despite these developments, IKNA shares are down 64.90% at $1.45.

Portfolio Pulse from Vandana Singh

November 09, 2023 | 6:20 pm

DIS

Disney (NYSE:DIS) reported Q4 financial results, with analysts praising the company's cost-cutting measures and potential for growth. Analysts from Raymond James, Rosenblatt, Morgan Stanley, Needham, Bank of America, and Goldman Sachs provided their insights, with most maintaining a positive outlook for the company. The company's direct-to-consumer segment, Disney+, saw good additions and improved operating losses. The potential return of Disney's dividend and share buybacks were also highlighted. Disney shares are up 7% to $90.79 on Thursday.

Portfolio Pulse from Chris Katje

November 09, 2023 | 6:19 pm

LTRN

Lantern Pharma's shares are trading higher following the company's announcement of better-than-expected Q3 GAAP EPS results.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:14 pm

ASTR

EVA

INBS

The article lists the stocks that gained and lost the most in Thursday's mid-day session. Among the gainers were Intelligent Bio Solutions Inc., Astra Space, Inc., and Tempest Therapeutics, Inc., which saw significant increases due to positive quarterly results and acquisition proposals. Among the losers were Enviva Inc., ContraFect Corporation, and Atara Biotherapeutics, Inc., which saw significant decreases due to poor quarterly results and disappointing clinical trial outcomes.

Portfolio Pulse from Lisa Levin

November 09, 2023 | 6:13 pm

CYN

Cyngn's shares are trading lower following the company's Q3 revenue results, which were worse than expected.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:08 pm

CUTR

Cutera's shares are trading lower following the company's Q3 revenue results, which were below expectations.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:07 pm

TOI

The Oncology Institute (TOI) reported better-than-expected Q3 revenue results, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 6:04 pm

VVV

Valvoline Inc. (NYSE:VVV) reported Q4 FY23 sales growth of 16% YoY to $390 million, beating the analyst consensus. The company registered an adjusted EPS of $0.39, missing the analyst consensus of $0.41. The company expects FY24 adjusted EPS of $1.40-$1.65, with net revenue of $1.6 billion-$1.7 billion. VVV shares are trading higher by 7.27% at $32.18.

Portfolio Pulse from Nabaparna Bhattacharya

November 09, 2023 | 6:03 pm

AFIB

Acutus Medical reported Q3 financial results and announced a strategic realignment of resources and corporate restructuring by approximately 65%. This has led to a decrease in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

November 09, 2023 | 5:59 pm